Skip to main content
Signal8

Abpro Holdings, Inc. (ABPO)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Abpro Holdings, Inc. logo

Abpro Holdings, Inc.

OTC:ABPOOTC (delisted from Nasdaq, Form 25 effective Oct 10, 2026)Healthcare
AH+0.00%$0.5337
Close$0.5337+0.70%
Mkt Cap$3.15M
EV-
Float5.01M
O/S5.9M
VOL23K sh
$ Vol$12K
RVOL1.36×
Inst Own0.3%
SI0.3%
Net Cash/Sh-
Dilution
Abpro Holdings, Inc. logoOTC:ABPOAH$0.5337+0.00%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20260.49000.53370.45000.533723,295
Nov 13, 20260.55300.56000.47000.53002,266
Nov 12, 20260.51000.62730.45100.510025,847
Nov 11, 20260.40500.57990.40500.536317,504
Nov 10, 20260.50000.50000.41250.499017,723
Nov 9, 20260.47000.58000.47000.55131,732
Nov 6, 20260.56270.62000.44100.577526,620
Nov 5, 20260.44500.57500.44500.56006,171
Nov 4, 20260.37510.53000.37510.500012,056
Nov 3, 20260.46000.48380.40500.48384,331
Nov 2, 20260.44970.45000.44320.44327,154
Oct 30, 20260.39750.43640.39000.436417,203
Oct 29, 20260.39990.42730.39990.42733,602
Oct 28, 20260.40000.43100.38000.431091,998
Oct 27, 20260.40250.40500.37000.39107,474
Oct 26, 20260.36500.43500.36450.391247,065
Oct 23, 20260.37610.42120.36560.42124,287
Oct 21, 20260.39000.42500.39000.400520,079
Oct 20, 20260.35570.39000.35570.39005,370
Oct 19, 20260.35700.40810.35700.4081548
Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
Not available
Ratings Distribution
BUY
0
HOLD
1
SELL
0
TOTAL1
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
0.3%
Institutional
(2)
-
Insiderⓘ
(3)
3.1%
5%+ Owners
(1)
-
Unattributed (incl. retail)ⓘ
Institutional0.3%
5%+ Beneficial3.1%
Sources: 13F, Form 4, 13D/13GO/S: 5.9M · as of 14 Aug 2026 · SEC filings
Insiders & Institutional Holders

Insiders

About

Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology.

The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration.

The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.

Key Metrics
Market Cap$3.15M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership0.34%

based on 5.90M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateMar 9, 2022
Shares Outstanding5.90M
Authorized Shares
Float5.01M
SEC Float (non-affiliate)5.06M
52-Week Range
$0.0866$7.34
$0.5337(6th percentile)
Volume
Average Daily Volume17.12K
23.30K today vs 17.12K avg(+36%)

30d Avg

17.12K

60d Avg

11.83K

90d Avg

17.62K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of ABPO as of Jun 30, 2026 records 3 outstanding warrant series and an offering closed Nov 7, 2025, from SEC filings. Abpro Holdings, Inc. (OTC: ABPO) traded at $0.5337 on Nov 17, 2026, up 0.70% from the previous close of $0.5300. 52-week range: $0.0866 to $7.34. The company is in the Healthcare sector (Biotechnology).